Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
Crossref DOI link: https://doi.org/10.1007/s00277-015-2486-9
Published Online: 2015-09-26
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
de Witte, Theo
Suciu, Stefan
Meert, Liv
Halkes, Constantijn
Selleslag, Dominik
Bron, Dominique
Amadori, Sergio
Willemze, Roel
Muus, Petra
Baron, Frédéric
License valid from 2015-09-26